|
1
|
Ferrari S, Smeland S, Mercuri M, et al:
Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose
methotrexate, cisplatin, and doxorubicin for patients with
localized osteosarcoma of the extremity: a joint study by the
Italian and Scandinavian Sarcoma Groups. J Clin Oncol.
23:8845–8852. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kager L, Zoubek A, Dominkus M, Lang S,
Bodmer N, Jundt G, Klingebiel T, Jürgens H, Gadner H and Bielack S;
COSS Study Group. Osteosarcoma in very young children: experience
of the Cooperative Osteosarcoma Study Group. Cancer. 116:5316–5324.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lewis VO: What’s new in musculoskeletal
oncology. J Bone Joint Surg Am. 89:1399–1407. 2007.
|
|
4
|
Stiller CA, Bielack SS, Jundt G and
Steliarova-Foucher E: Bone tumours in European children and
adolescents, 1978–1997. Report from the Automated Childhood Cancer
Information System project. Eur J Cancer. 42:2124–2135. 2006.
|
|
5
|
Campbell CJ, Cohen J and Enneking WF:
Editorial: New therapies for osteogenic sarcoma. J Bone Joint Surg
Am. 57:143–144. 1975.PubMed/NCBI
|
|
6
|
Kawaguchi S, Wada T, Tsukahara T, Ida K,
Torigoe T, Sato N and Yamashita T: A quest for therapeutic antigens
in bone and soft tissue sarcoma. J Transl Med. 3:312005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soanes WA, Ablin RJ and Gonder MJ:
Remission of metastatic lesions following cryosurgery in prostatic
cancer: immunologic considerations. J Urol. 104:154–159.
1970.PubMed/NCBI
|
|
8
|
Sabel MS: Cryo-immunology: a review of the
literature and proposed mechanisms for stimulatory versus
suppressive immune responses. Cryobiology. 58:1–11. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kawano M, Nishida H, Nakamoto Y, Tsumura H
and Tsuchiya H: Cryoimmunologic antitumor effects enhanced by
dendritic cells in osteosarcoma. Clin Orthop Relat Res.
468:1373–1383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nishida H, Tsuchiya H and Tomita K:
Re-implantation of tumour tissue treated by cryotreatment with
liquid nitrogen induces anti-tumour activity against murine
osteosarcoma. J Bone Joint Surg Br. 90:1249–1255. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
den Brok MH, Sutmuller RP, Nierkens S,
Bennink EJ, Toonen LW, Figdor CG, et al: Synergy between in situ
cryoablation and TLR9 stimulation results in a highly effective in
vivo dendritic cell vaccine. Cancer Res. 66:7285–7292.
2006.PubMed/NCBI
|
|
12
|
Redondo P, del Olmo J, López-Diaz de Cerio
A, Inoges S, Marquina M, Melero I and Bendandi M: Imiquimod
enhances the systemic immunity attained by local cryosurgery
destruction of melanoma lesions. J Invest Dermatol. 127:1673–1680.
2007.PubMed/NCBI
|
|
13
|
Wing K, Onishi Y, Prieto-Martin P, et al:
CTLA-4 control over Foxp3+ regulatory T cell function.
Science. 322:271–275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang B, Workman C, Lee J, et al:
Regulatory T cells inhibit dendritic cells by lymphocyte activation
gene-3 engagement of MHC class II. J Immunol. 180:5916–5926. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Viguier M, Lemaître F, Verola O, et al:
Foxp3 expressing CD4+CD25(high) regulatory T cells are
overrepresented in human metastatic melanoma lymph nodes and
inhibit the function of infiltrating T cells. J Immunol.
173:1444–1453. 2004.PubMed/NCBI
|
|
16
|
Leach DR, Krummel MF and Allison JP:
Enhancement of antitumor immunity by CTLA-4 blockade. Science.
271:1734–1736. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hurwitz AA, Yu TF, Leach DR and Allison
JP: CTLA-4 blockade synergizes with tumor-derived
granulocyte-macrophage colony-stimulating factor for treatment of
an experimental mammary carcinoma. Proc Natl Acad Sci USA.
95:10067–10071. 1998. View Article : Google Scholar
|
|
18
|
van Elsas A, Hurwitz AA and Allison JP:
Combination immunotherapy of B16 melanoma using anti-cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage
colony-stimulating factor (GM-CSF)-producing vaccines induces
rejection of subcutaneous and metastatic tumors accompanied by
autoimmune depigmentation. J Exp Med. 190:355–366. 1999.
|
|
19
|
Demaria S, Kawashima N, Yang AM, Devitt
ML, Babb JS, Allison JP and Formenti SC: Immune-mediated inhibition
of metastases after treatment with local radiation and CTLA-4
blockade in a mouse model of breast cancer. Clin Cancer Res.
11:728–734. 2005.PubMed/NCBI
|
|
20
|
Small EJ, Sacks N, Nemunaitis J, Urba WJ,
Dula E, Centeno AS, et al: Granulocyte macrophage
colony-stimulating factor-secreting allogeneic cellular
immunotherapy for hormone-refractory prostate cancer. Clin Cancer
Res. 13:3883–3891. 2007. View Article : Google Scholar
|
|
21
|
Hodi FS, O’Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, et al: Improved survival with ipilimumab in
patients with metastatic melanoma. N Engl J Med. 363:711–723. 2010.
View Article : Google Scholar
|
|
22
|
Lutz MB and Rössner S: Factors influencing
the generation of murine dendritic cells from bone marrow: the
special role of fetal calf serum. Immunobiology. 212:855–862. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sabel MS, Arora A, Su G and Chang AE:
Adoptive immunotherapy of breast cancer with lymph node cells
primed by cryoablation of the primary tumor. Cryobiology.
53:360–366. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sabel MS, Nehs MA, Su G, Lowler KP,
Ferrara JLM and Chang AE: Immunologic response to cryoablation of
breast cancer. Breast Cancer Res Treat. 90:97–104. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Urano M, Tanaka C, Sugiyama Y, Miya K and
Saji S: Antitumor effects of residual tumor after cryoablation: the
combined effect of residual tumor and a protein-bound
polysaccharide on multiple liver metastases in a murine model.
Cryobiology. 46:238–245. 2003. View Article : Google Scholar
|
|
26
|
Yang YF, Zou JP, Mu J, Wijesuriya R, Ono
S, Walunas T, Bluestone J, Fujiwara H and Hamaoka T: Enhanced
induction of antitumor T-cell responses by cytotoxic T
lymphocyte-associated molecule-4 blockade: the effect is manifested
only at the restricted tumor-bearing stages. Cancer Res.
57:4036–4041. 1997.PubMed/NCBI
|
|
27
|
Persson J, Beyer I, Yumul R, et al:
Immuno-therapy with anti-CTLA4 antibodies in tolerized and
non-tolerized mouse tumor models. PLoS One. 6:223032011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shrikant P, Khoruts A and Mescher MF:
CTLA-4 blockade reverses CD8+ T cell tolerance to tumor
by a CD4+ T cell- and IL-2-dependent mechanism.
Immunity. 11:483–493. 1999.PubMed/NCBI
|
|
29
|
Traynor K: Ipilimumab approved for
metastatic melanoma. Am J Health Syst Pharm. 68:7682011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hersh EM, O’Day SJ, Powderly J, et al: A
phase II multicenter study of ipilimumab with or without
dacarbazine in chemotherapy-naïve patients with advanced melanoma.
Invest New Drugs. 29:489–498. 2011.
|
|
31
|
Lynch TJ, Bondarenko I, Luft A,
Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H,
Cuillerot JM and Reck M: Ipilimumab in combination with paclitaxel
and carboplatin as first-line treatment in stage IIIB/IV
non-small-cell lung cancer: results from a randomized,
double-blind, multicenter phase II study. J Clin Oncol.
30:2046–2054. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bacci G, Briccoli A, Rocca M, Ferrari S,
Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C,
Manfrini M and Galletti S: Neoadjuvant chemotherapy for
osteosarcoma of the extremities with metastases at presentation:
recent experience at the Rizzoli Institute in 57 patients treated
with cisplatin, doxorubicin, and a high dose of methotrexate and
ifosfamide. Ann Oncol. 14:1126–1134. 2003. View Article : Google Scholar
|
